Skip to main content
. 2021 Feb 17;21(1):e2. doi: 10.4110/in.2021.21.e2

Table 2. A list of SARS-CoV-2-derived CD4+ T-cell epitopes that have been tested in unexposed individuals or examined for cross-reactivity with human CCCoVs.

Protein AA sequence Position HLA allele Epitope-reactive T cell response in unexposed individuals Confirmed cross-reactivity with CCCoVs Detection method Ref.
N MKDLSPRWYFYYLGT 101-115 ND + ND Ex vivo IFN-γ ELISpot and ICS assay (24)
N PRWYFYYLGTGPEAG 106-120 ND + ND
ORF1a SKLWAQCVQLHNDIL 26-40 ND + ND
ORF1a HNDILLAKDTTEAFE 36-50 ND +
S ITRFQTLLALHRSYL 235-249 DRB1*01 + ND Pre-expansion → IFN-γ ELISpot (37)
M LSYYKLGASQRVAGD 176-190 DRB1*04, DRB1*07 ND
N ASWFTALTQHGKEDL 50-64 DRB1*04, DRB1*11 + ND
N IGYYRRATRRIRGGD 84-98 DRB1*04, DRB1*11 ND
N RWYFYYLGTGPEAGL 107-121 DRB1*04 + ND
N KDGIIWVATEGALNT 127-141 DRB1*01, DRB1*04, DRB1*11 + ND
N AIVLQLPQGTTLPKG 156-170 DRB1*01, DRB1*03 ND
N YKHWPQIAQFAPSAS 298-312 DRB1*01, DRB1*04, DRB1*11 ND
N ASAFFGMSRIGMEVT 311-325 DRB1*01, DRB1*04, DRB1*07, DRB1*11 + ND
N GTWLTYTGAIKLDDK 328-342 DRB1*01, DRB1*07, DRB1*15 + ND
N AIVLQLPQGTTLPKG 156-170 DRB1*01, DRB1*03 ND
E FYVYSRVKNLNSSRV 56-70 DRB1*04, DRB1*11 + ND
ORF1 LDDFVEIIKSQDLSV 6751-6765 DRB1*11 + ND
ORF3 FMRIFTIGTVTLKQG 4-18 DRB1*01, DRB1*03, DRB1*07 + ND
ORF6 IWNLDYIINLIIKNL 26-40 DRB1*04, DRB1*07, DRB1*15 + ND
ORF7 QEEVQELYSPIFLIV 90-104 DRB1*01, DRB1*07 + ND
ORF8 SKWYIRVGARKSAPL 43-57 DRB1*01, DRB1*11 + ND
ORF10 INVFAFPFTIYSLLL 4-18 DRB1*01, DRB1*04 ND
N LLLLDRLNQLESKMS 221-235 DRB1*04, DRB1*15 + ND
N LLLLDRLNQLESKMS 221-235 DRB1*11:01, DQA1*01:01, DQB1*05:01 + ND Pre-expansion → IFN-γ/IL-5 FluoroSPOT (36)
S SLLIVNNATNVVIKV 116-130 DRB1*07:01, *13:01, DQA1*01:03/DQB1*06:03 +
S NNATNVVIKVCEFQF 121-135 ND + ND
S CEFQFCNDPFLGVYY 131-145 DQA1*02:01/DQB1*02:02, *01:01/*05:01 + ND
S CTFEYVSQPFLMDLE 166-180 DQA1*01:02/DQB1*06:04 +
S IGINITRFQTLLALH 231-245 DRB1*07:01, *11:02, *13:01, *13:03, DQA1*01:03/DQB1*06:03 + ND
S TRFQTLLALHRSYLT 236-250 DRB1*01:01, *07:01, *08:03, DRB1*11:02, *13:01, *13:02, *13:03, DRB1*15:01, DQA1*01:01/DQB1*05:01, *01:02/*06:02, *01:03/*06:03 +
S LLALHRSYLTPGDSS 241-255 DRB1*01:01, *07:01, *11:02, *15:01 + ND
S FTVEKGIYQTSNFRV 306-320 ND + ND
S SNFRVQPTESIVRFP 316-330 DRB1*03:01 + ND
S QPTESIVRFPNITNL 321-335 DRB1*08:03, *15:01 +
S IVRFPNITNLCPFGE 326-340 ND +
S CPFGEVFNATRFASV 336-350 DRB1*01:01, *08:03, *11:01, *11:02, *13:03, DQA1*05:01/DQB1*03:01, *01:02/*06:02 +
S VFNATRFASVYAWNR 341-355 DRB1*01:01, *08:03, *11:01, *13:03, *15:01, DQA1*05:01/DQB1*03:01, *01:02/*06:02 +
S SIIAYTMSLGAENSV 691-705 DRB1*01:03, *07:01, DQA1*02:01/DQB1*02:02, *01:01/*05:01 + ND
S AYSNNSIAIPTNFTI 706-720 DQA1*01:03/DQB1*06:03 +
S NLLLQYGSFCTQLNR 751-765 DRB1*01:01, *15:01, DQA1*01:01/DQB1*05:01 + ND
S TQLNRALTGIAVEQD 761-775 DRB1*01:01, *09:01, DQA1*03:01/DQB1*03:03, *03:01/*04:02, *01:02/*06:02, *01:02/*06:04 +
S VFAQVKQIYKTPPIK 781-795 ND +
S NFSQILPDPSKPSKR 801-815 ND + ND
S KPSKRSFIEDLLFNK 811-825 DRB1*03:01, DQA1*05:01/DQB1*02:01, *02:01/*02:02, *01:01/*05:01 + ND
S SFIEDLLFNKVTLAD 816-830 DRB1*01:01, *01:03, *04:04, *11:02, *13:03, *14:01, *15:01, *16:02, DQA1*01:01/DQB1*05:01, *01:02, *05:02 + +
S AQYTSALLAGTITSG 871-885 ND + ND
S WTFGAGAALQIPFAM 886-900 DRB1*01:01, DQA1*05:01/DQB1*03:01 + ND
S AQALNTLVKQLSSNF 956-970 DRB1*11:01, *13:03, DQA1*01:02/DQB1*06:02 + ND
S GAISSVLNDILSRLD 971-985 DQA1*01:01/DQB1*05:01 +
S VQIDRLITGRLQSLQ 991-1005 DRB1*01:01, *03:01, *11:01, *13:03 +
S APHGVVFLHVTYVPA 1056-1070 DRB1*04:04, *10:01, DQA1*01:01/DQB1*05:01 + ND
S ELDKYFKNHTSPDVD 1151-1165 ND +
S GINASVVNIQKEIDR 1171-1185 DQA1*05:01/DQB1*03:01 +
S LNEVAKNLNESLIDL 1186-1200 DRB1*13:02 +
S YEQYIKWPWYIWLGF 1206-1220 ND + +
N DAALALLLLDRLNQL 216-230 DRB1*11:01, DQA1*01:01/DQB1*05:01 +
N PSGTWLTYTGAIKLD 326-340 DRB1*01:03, *07:01 + +
E LAILTALRLCAYCCN 31-45 DRB1*01:01, *11:01 + ND
ORF1a PLNSIIKTIQPRVEK 276-290 DRB1*01:01, *07:01 +
ORF1a EEIAIILASFSASTS 471-485 DRB1*04:10, *07:01, DQA1*02:01/DQB1*02:02, *03:01/*03:02 +
ORF1a SPLYAFASEAARVVR 531-545 DRB1*07:01, DQA1*02:01/DQB1*02:02 +
ORF1a QTFFKLVNKFLALCA 676-690 DRB1*01:03, *07:01, DQA1*01:01/DQB1*05:01 +
ORF1a GETFVTHSKGLYRKC 706-720 DRB1*07:01 + ND
ORF1a KVTFFPDLNGDVVAI 1956-1970 DQA1*02:01/DQB1*02:02, *01:01/*05:01 + ND
ORF1a SHNIALIWNVKDFMS 2706-2720 DRB1*04:10, DQA1*02:01/DQB1*02:02, *03:01/*03:02, *03:01/*04:02 + ND
ORF1a KHFYWFFSNYLKRRV 3151-3165 DRB1*04:10, *0701, *09:01, DQA1*02:01/DQB1*02:02, *03:01/*04:02 +
ORF1a NHNFLVQAGNVQLRV 3326-3340 DRB1*01:01, *07:01, *08:03, *15:01, DQA1*05:01/DQB1*03:01, *01:02/*06:02 +
ORF1a QNCVLKLKVDTANPK 3346-3360 DRB1*04:10 + ND
ORF1a NRYFRLTLGVYDYLV 3801-3815 DRB1*01:01, *01:03, *07:01, *08:03, *15:01, DQA1*02:01/DQB1*02:02, *01:01/*05:01, *01:02/*06:02 +
ORF1a VLKKLKKSLNVAKSE 3976-3990 DRB1*11:01, *13:03, DQA1*01:02/DQB1*06:02 + +
ORF1b KLLKSIAATRGATVV 4966-4980 DRB1*04:04, *10:01 + +
ORF1b EFYAYLRKHFSMMIL 5136-5150 DRB1*07:01, *09:01, *13:01, DQA1*03:01/DQB1*04:02 + +
ORF1b GLVASIKNFKSVLYY 5166-5180 DRB1*08:03, *12:02, DQA1*01:03/DQB1*06:01 + ND
ORF1b LMIERFVSLAIDAYP 5246-5260 DRB1*01:03, *07:01, *08:03, *12:02, DQA1*02:01/DQB1*02:02, *05:01/*03:01, *01:01/*05:01, *01:03/*06:01 + +
ORF1b TSHKLVLSVNPYVCN 5361-5375 DRB1*07:01, *13:01, DQA1*01:03/DQB1*06:03 + +
ORF1b ISPYNSQNAVASKIL 5836-5850 DRB1*01:01, DQA1*01:02/DQB1*06:02 + ND
ORF1b NVNRFNVAITRAKVG 5881-5895 DRB1*08:03, *15:01, DQA1*05:01/DQB1*03:01, *01:02/*06:02 + +
ORF1b REEAIRHVRAWIGFD 6001-6015 DRB1*01:03, *07:01 + ND
ORF1b TQLCQYLNTLTLAVP 6846-6860 DRB1*01:01, *15:01, DQA1*01:01/DQB1*05:01, *01:02/*06:02 + ND
ORF3a SDFVRATATIPIQAS 26-40 DRB1*07:01, DQA1*02:01/DQB1*02:02 +
ORF3a ALLAVFQSASKIITL 51-65 DRB1*07:01, *13:01, DQA1*01:03/DQB1*06:03 +
ORF6 MFHLVDFQVTIAEIL 1-15 DRB1*13:03 +
ORF6 TFKVSIWNLDYIINL 21-35 DRB1*01:03, *07:01, *15:01, DQA1*02:01/DQB1*02:02, *01:01/*05:01 +
ORF6 YIINLIIKNLSKSLT 31-45 DRB1*11:02, *13:03 +
ORF7 VKHVYQLRARSVSPK 71-85 DRB1*01:03, *07:01 +
ORF8 FYSKWYIRVGARKSA 41-55 DRB1*01:01, *07:01 +

AA, amino acid; HLA, human leukocyte antigen; E, envelope; +, positive response; −, negative response; ND, not determined.